Commodore Capital LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001831942
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2024 · 35 positions · Total reported value $1.47B · Top-10 concentration 63.8% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 53.7% · 5 new · 9 cut · 8 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +32.0% · vs SPY +17.2% · Prev Value $1.73B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2024 13F filing, Commodore Capital LP disclosed 35 equity positions with a combined reported value of $1.47B. The filing implies a focused portfolio: its ten largest positions account for 63.8% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2024 were MRUS ($189.34M), NUVL ($112.86M), XENE ($107.39M). By sector, the heaviest allocations are Health Care 68.8%, Other 31.2%.
Versus the prior quarter, Commodore Capital LP opened 5 new positions, trimmed 9 and fully exited 8, a turnover rate of 53.7% of positions. The portfolio's overlap with the prior quarter was 72% of names.
The largest new positions opened in Q2 2024 were ALKS ($33.14M), PCSC ($7.54M), ABIO ($1.59M).
Of the 8 positions fully exited versus the prior quarter, the largest were ALPN ($54.51M), KYTX ($22.66M), ENGN ($21.19M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2024)
Fully Exited (vs previous quarter)
- ALPN ALPINE IMMUNE SCIENCES INC · prev qtr: $54.51M
- KYTX KYVERNA THERAPEUTICS INC · prev qtr: $22.66M
- ENGN ENGENE THERAPEUTICS INC · prev qtr: $21.19M
- ADVM ADVERUM BIOTECHNOLOGIES INC · prev qtr: $9.29M
- MGNX MACROGENICS INC · prev qtr: $4.34M
- ACET ADICET BIO INC · prev qtr: $3.23M
- SABS SAB BIOTHERAPEUTICS INC · prev qtr: $831.61K · history
- DBVT DBV TECHNOLOGIES S A · prev qtr: $69.43K
Insider Transactions (Form 4)
Latest Commodore Capital LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Commodore Capital LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 33 positions worth $1.68B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-117168 (status: Approved), registered 2019-08-12
- Regulatory AUM (Form ADV): $2.37B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
- Website: commodorecapital.com
Portfolio Structure
- 33 positions · $1.68B reported value (Q2 2026)
- Top 10 holdings = 68.2% of reported value
- Largest position: RLAY (RELAY THERAPEUTICS INC COM) at 13.4%
- Average position size: $50.88M
Sector Tilt
- Health Care 94.7%
- Industrials 3.9%
- Financials 0.6%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q2 2026: 5 new, 6 added, 9 reduced, 8 exited
- 13 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
3.20M | $189.34M | 12.92% | Reduce | |
| 2 |
|
1.49M | $112.86M | 7.70% | Hold | |
| 3 |
|
2.75M | $107.39M | 7.33% | Add | |
| 4 |
|
1.30M | $98.54M | 6.73% | Add | |
| 5 |
|
3.97M | $92.85M | 6.34% | Hold | |
| 6 |
|
2.48M | $89.55M | 6.11% | Reduce | |
| 7 |
|
9.74M | $82.09M | 5.60% | Add | |
| 8 |
|
1.43M | $58.14M | 3.97% | Add | |
| 9 |
|
1.43M | $52.74M | 3.60% | Add | |
| 10 |
|
7.15M | $51.52M | 3.52% | Add | |
| 11 |
|
1.23M | $50.30M | 3.43% | Add | |
| 12 |
|
1.88M | $50.16M | 3.42% | Add | |
| 13 |
|
1.99M | $46.74M | 3.19% | Add | |
| 14 |
|
4.66M | $46.43M | 3.17% | Reduce | |
| 15 |
|
1.81M | $34.03M | 2.32% | Add | |
| 16 |
|
1.38M | $33.14M | 2.26% | New | |
| 17 |
|
2.53M | $32.89M | 2.25% | Add | |
| 18 |
|
1.59M | $32.81M | 2.24% | Add | |
| 19 |
|
4.15M | $24.53M | 1.68% | Add | |
| 20 |
|
1.46M | $23.98M | 1.64% | Reduce | |
| 21 |
|
1.55M | $20.09M | 1.37% | Add | |
| 22 |
|
750.99K | $19.83M | 1.35% | Hold | |
| 23 |
|
1.28M | $16.98M | 1.16% | Reduce | |
| 24 |
|
825.00K | $16.94M | 1.16% | Add | |
| 25 |
|
3.41M | $15.76M | 1.07% | Hold | |
| 26 |
|
2.00M | $14.14M | 0.96% | Hold | |
| 27 |
|
290.00K | $11.41M | 0.78% | Hold | |
| 28 |
|
1.10M | $8.23M | 0.56% | Hold | |
| 29 |
|
750.00K | $7.54M | 0.52% | New | |
| 30 |
|
200.00K | $7.28M | 0.50% | Hold | |
| 31 |
|
1.57M | $5.48M | 0.37% | Hold | |
| 32 |
|
500.00K | $5.11M | 0.35% | Hold | |
| 33 |
|
1.18M | $4.10M | 0.28% | Reduce | |
| 34 |
|
414.32K | $1.59M | 0.11% | New | |
| 35 |
|
40.00K | $498.80K | 0.03% | New | |
FAQ
What did Commodore Capital LP buy in 2024-Q2?
In its 2024-Q2 13F filing, Commodore Capital LP reported 35 equity positions worth $1.47B in aggregate; its largest disclosed positions were MRUS ($189.34M), NUVL ($112.86M), XENE ($107.39M).
How large is Commodore Capital LP's portfolio?
Commodore Capital LP reported $1.47B of long equity holdings across 35 positions as of 2024-Q2. Top-10 holdings account for 63.8% of reported value.
What is Commodore Capital LP's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.